AR056310A1 - Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos - Google Patents
Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usosInfo
- Publication number
- AR056310A1 AR056310A1 ARP060101440A ARP060101440A AR056310A1 AR 056310 A1 AR056310 A1 AR 056310A1 AR P060101440 A ARP060101440 A AR P060101440A AR P060101440 A ARP060101440 A AR P060101440A AR 056310 A1 AR056310 A1 AR 056310A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- nhet
- hal
- mnr5r6
- ncyc
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 150000003212 purines Chemical class 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los compuestos de la formula I en donde X es OH o NH2, R1 es H o A, R2, R3 son en cada caso, de modo independiente entre sí, H, A, Hal, OH, OA o CN, R4 es Ar o Het1, R5, R6 son en cada caso, de modo independiente entre sí, H o A, A es fenilo, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo con 2 a 6 átomos de C, alquinilo con 2 a 6 átomos de C, NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, fenilo, (CH2) nHet, O(CH2) nHet, NH(CH2) nHet, O(CH2)nCyc, NH(CH2)nCyc, O(CH2)mNR5R6, NR1(CH2)mNR5R6 y/u O(CH2)mNR1 (CH2)mOR1, Het1 es un heterociclo aromático mono- o bibíclico con 1 a 4 átomos de N, O Y/o S, que no está sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo con 2 a 6 átomos de C, alquinilo con 2 a 6 átomos de C, NO2, NR5R6, CONR5R6, COOH, COOA, CN, CHO, COA, fenilo, (CH2)nHet, O(CH2)nHet, O(CH2)nCyc, NH(CH2)nCyc, O(CH2)mNR5r6, NR1(CH2)mNR5R6 y/u O(CH2)mNR1(CH2)mOR1, Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, fenilo, COOA, CN y/u oxígeno del carbonilo (=O), A es alquilo con 1 a 10 átomos de C, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o cloro, Cyc es cicloalquilo con 3 a 7 átomos de C, Hal es F, Cl, Br o I, n es 0, 1, 2, 3 o 4, m es 1, 2, 3 o 4, así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la TIE-2, y de las Raf-quinasas, y pueden utilizarse, p.ej., para el tratamiento de tumores. Proceso de preparacion de dichos compuestos y composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005017259A DE102005017259A1 (de) | 2005-04-14 | 2005-04-14 | Purinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056310A1 true AR056310A1 (es) | 2007-10-03 |
Family
ID=36579893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101440A AR056310A1 (es) | 2005-04-14 | 2006-04-12 | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080214582A1 (es) |
| EP (1) | EP1869047A1 (es) |
| JP (1) | JP2008535874A (es) |
| AR (1) | AR056310A1 (es) |
| AU (1) | AU2006233530A1 (es) |
| CA (1) | CA2604294A1 (es) |
| DE (1) | DE102005017259A1 (es) |
| WO (1) | WO2006108482A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| WO2013077921A2 (en) * | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2016049774A1 (en) * | 2014-10-03 | 2016-04-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders |
| JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
| JP7416716B2 (ja) | 2017-12-28 | 2024-01-17 | トラクト ファーマシューティカルズ インコーポレイテッド | 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法 |
| CN115710281B (zh) * | 2022-11-14 | 2024-05-17 | 南京中医药大学 | 一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1438048A1 (en) * | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| JP2007502776A (ja) * | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｒｔｋ阻害剤としての６−置換アニリノプリン類 |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
-
2005
- 2005-04-14 DE DE102005017259A patent/DE102005017259A1/de not_active Withdrawn
-
2006
- 2006-03-15 CA CA002604294A patent/CA2604294A1/en not_active Abandoned
- 2006-03-15 US US11/910,776 patent/US20080214582A1/en not_active Abandoned
- 2006-03-15 AU AU2006233530A patent/AU2006233530A1/en not_active Abandoned
- 2006-03-15 JP JP2008505752A patent/JP2008535874A/ja active Pending
- 2006-03-15 EP EP06723450A patent/EP1869047A1/de not_active Withdrawn
- 2006-03-15 WO PCT/EP2006/002380 patent/WO2006108482A1/de not_active Ceased
- 2006-04-12 AR ARP060101440A patent/AR056310A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080214582A1 (en) | 2008-09-04 |
| AU2006233530A1 (en) | 2006-10-19 |
| JP2008535874A (ja) | 2008-09-04 |
| EP1869047A1 (de) | 2007-12-26 |
| DE102005017259A1 (de) | 2006-10-19 |
| WO2006108482A1 (de) | 2006-10-19 |
| CA2604294A1 (en) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| PE20090964A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b | |
| AR046929A1 (es) | Piridopirimidinonas | |
| AR037972A1 (es) | Pirrolopirimidinas | |
| AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
| AR096235A1 (es) | Arilquinazolinas | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| AR066543A1 (es) | Derivados de piridazinona | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR060608A1 (es) | Inhibidores de la quinasa c- fms | |
| DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| PE20161443A1 (es) | Compuestos | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| GT200600143A (es) | Fenilacetamidas apropiadas como inhibidores de la proteina kinasa | |
| AR043833A1 (es) | Derivados de 1,2 diazol. metodo de preparacion y composiciones farmaceuticas | |
| AR068872A1 (es) | 5- ciano- tienopiridinas. procesos de obtencion y composiciones farmaceuticas. | |
| AR046227A1 (es) | Uso de tienopirimidinas en la preparacion de medicamentos para el tratamiento de tumores. | |
| AR059293A1 (es) | Derivados de aminoindazol, procesos de obtencion y composiciones farmaceuticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |